A phase I/II pharmacokinetics/pharmacodynamics study of irinotecan combined with S−1 for recurrent/metastatic breast cancer in patients with selected UGT1A1 genotypes (the JBCRG‐M01 study)

S‐1 and irinotecan combination is attractive for breast cancer refractory to anthracyclines and taxanes. Patients with advanced human epidermal growth factor receptor 2 (HER2)‐negative breast cancer previously treated with anthracyclines and taxanes were eligible. Patients with brain metastases and...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cancer Med
Autori principali: Ishiguro, Hiroshi, Saji, Shigehira, Nomura, Shogo, Tanaka, Sunao, Ueno, Takayuki, Onoue, Masahide, Iwata, Hiroji, Yamanaka, Takeharu, Sasaki, Yasutsuna, Toi, Masakazu
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley and Sons Inc. 2017
Soggetti:
Clinical Cancer Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5727322/
https://ncbi.nlm.nih.gov/pubmed/29131533
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.1258
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi